Company Harrow, Inc.

HROW

US4158581094

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Ratings for Harrow, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 12:37:32 30/04/2024 am IST			5-day change	1st Jan Change
10.56 ^USD	+0.24%		+0.66%	-4.73%

11/04	Craig-Hallum Starts Harrow With Buy Rating, $24 Price Target	MT
22/03	B. Riley Securities Adjusts Harrow Health's Price Target to $26 From $30, Maintains Buy Rating	MT

Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.

Number of employees: 315

USD in Million	2022	Weight	2023	Weight	Delta
Innovative Ophthalmic Therapies 100.0 %	89	100.0 %	130	100.0 %	+46.95%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	89	100.0 %	130	100.0 %	+46.95%

Managers	Title	Age	Since
Mark Baum CEO	Chief Executive Officer	51	01/06/01
Andrew Boll DFI	Director of Finance/CFO	41	01/11/01
Jamie Webb IRC	Investor Relations Contact	-	-
Kim Barratt HRO	Human Resources Officer	-	01/22/01
Dennis E. Saadeh PRN	Corporate Officer/Principal	-	-
Mark Mannebach LAW	General Counsel	-	06/23/06
John Saharek PRN	Corporate Officer/Principal	64	01/12/01

Members of the board	Title	Age	Since
Mark Baum CEO	Chief Executive Officer	51	01/06/01
Lauren Silvernail BRD	Director/Board Member	65	26/01
Adrienne Graves BRD	Director/Board Member	69	26/01
Teresa Sparks BRD	Director/Board Member	55	16/20/16
Perry J. Sternberg BRD	Director/Board Member	55	31/22/31
Marty Makary BRD	Director/Board Member	53	31/22/31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	35,362,642	30,204,168 ( 85.41 %)	0	85.41 %

Name	Equities	%	Valuation
Opaleye Management, Inc. 10.80 %	3,820,000	10.80 %	51 M $
Opaleye Management, Inc. 10.79 %	3,815,000	10.79 %	50 M $
Private Capital Management LLC 7.902 %	2,794,497	7.902 %	37 M $
Mark Baum 6.045 %	2,137,525	6.045 %	28 M $
BlackRock Advisors LLC 5.945 %	2,102,134	5.945 %	28 M $
Daniel Kaufman 5.394 %	1,907,332	5.394 %	25 M $
Vanguard Fiduciary Trust Co. 5.114 %	1,808,552	5.114 %	24 M $
Braidwell LP 4.238 %	1,498,584	4.238 %	20 M $
Morgan Stanley Investment Management, Inc. 3.865 %	1,366,741	3.865 %	18 M $
DWS Investment Management Americas, Inc. 2.118 %	748,855	2.118 %	10 M $

Name	Equities	%	Valuation
ETON PHARMACEUTICALS, INC. 7.72%	1,982,000	7.72%	7,432,500 $

Harrow, Inc.

102 Woodmont Boulevard Suite 610

37205, Nashville

http://www.harrowinc.com

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.53 USD

Average target price

26.65 USD

Spread / Average Target

+153.09%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
HARROW, INC.	-4.73%	372M
ELI LILLY AND COMPANY	+25.80%	661B
NOVO NORDISK A/S	+26.74%	566B
JOHNSON & JOHNSON	-6.69%	352B
MERCK & CO., INC.	+19.01%	332B
ABBVIE INC.	+3.22%	283B
ASTRAZENECA PLC	+13.43%	231B
NOVARTIS AG	+4.71%	200B
ROCHE HOLDING AG	-9.53%	195B
AMGEN INC.	-4.23%	145B

Other Pharmaceuticals